332 related articles for article (PubMed ID: 19318628)
1. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.
Wheeler CM; Hunt WC; Joste NE; Key CR; Quint WG; Castle PE
J Natl Cancer Inst; 2009 Apr; 101(7):475-87. PubMed ID: 19318628
[TBL] [Abstract][Full Text] [Related]
2. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
3. Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.
Brotherton JML; Tabrizi SN; Phillips S; Pyman J; Cornall AM; Lambie N; Anderson L; Cummings M; Payton D; Scurry JP; Newman M; Sharma R; Saville M; Garland SM
Int J Cancer; 2017 Oct; 141(8):1576-1584. PubMed ID: 28677147
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial.
Monsonego J; Cox JT; Behrens C; Sandri M; Franco EL; Yap PS; Huh W
Gynecol Oncol; 2015 Apr; 137(1):47-54. PubMed ID: 25667973
[TBL] [Abstract][Full Text] [Related]
5. Primary and secondary prevention of cervical cancer--opportunities and challenges.
Markowitz LE; Unger ER; Saraiya M
J Natl Cancer Inst; 2009 Apr; 101(7):439-40. PubMed ID: 19318638
[No Abstract] [Full Text] [Related]
6. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
de Sanjose S; Quint WG; Alemany L; Geraets DT; Klaustermeier JE; Lloveras B; Tous S; Felix A; Bravo LE; Shin HR; Vallejos CS; de Ruiz PA; Lima MA; Guimera N; Clavero O; Alejo M; Llombart-Bosch A; Cheng-Yang C; Tatti SA; Kasamatsu E; Iljazovic E; Odida M; Prado R; Seoud M; Grce M; Usubutun A; Jain A; Suarez GA; Lombardi LE; Banjo A; Menéndez C; Domingo EJ; Velasco J; Nessa A; Chichareon SC; Qiao YL; Lerma E; Garland SM; Sasagawa T; Ferrera A; Hammouda D; Mariani L; Pelayo A; Steiner I; Oliva E; Meijer CJ; Al-Jassar WF; Cruz E; Wright TC; Puras A; Llave CL; Tzardi M; Agorastos T; Garcia-Barriola V; Clavel C; Ordi J; Andújar M; Castellsagué X; Sánchez GI; Nowakowski AM; Bornstein J; Muñoz N; Bosch FX;
Lancet Oncol; 2010 Nov; 11(11):1048-56. PubMed ID: 20952254
[TBL] [Abstract][Full Text] [Related]
7. Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention.
Castellsagué X; Klaustermeier J; Carrilho C; Albero G; Sacarlal J; Quint W; Kleter B; Lloveras B; Ismail MR; de Sanjosé S; Bosch FX; Alonso P; Menéndez C
Int J Cancer; 2008 Apr; 122(8):1901-4. PubMed ID: 18076064
[TBL] [Abstract][Full Text] [Related]
8. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada.
Coutlée F; Ratnam S; Ramanakumar AV; Insinga RR; Bentley J; Escott N; Ghatage P; Koushik A; Ferenczy A; Franco EL
J Med Virol; 2011 Jun; 83(6):1034-41. PubMed ID: 21503917
[TBL] [Abstract][Full Text] [Related]
9. Age-specific occurrence of HPV16- and HPV18-related cervical cancer.
de Sanjose S; Wheeler CM; Quint WGV; Hunt WC; Joste NE; Alemany L; Bosch FX; ; Myers ER; Castle PE
Cancer Epidemiol Biomarkers Prev; 2013 Jul; 22(7):1313-1318. PubMed ID: 23632816
[TBL] [Abstract][Full Text] [Related]
10. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine.
Hooi DJ; Lissenberg-Witte BI; de Koning MNC; Pinedo HM; Kenter GG; Meijer CJ; Quint WG
Sex Transm Infect; 2018 Jun; 94(4):263-267. PubMed ID: 29021405
[TBL] [Abstract][Full Text] [Related]
12. Distribution of human papillomavirus types in cervical cancers in Hong Kong: current situation and changes over the last decades.
Chan PK; Ho WC; Yu MY; Pong WM; Chan AC; Chan AK; Cheung TH; Wong MC; To KF; Ng HK
Int J Cancer; 2009 Oct; 125(7):1671-7. PubMed ID: 19507252
[TBL] [Abstract][Full Text] [Related]
13. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
Kjær SK; Frederiksen K; Munk C; Iftner T
J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
[TBL] [Abstract][Full Text] [Related]
14. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.
Mesher D; Cuschieri K; Hibbitts S; Jamison J; Sargent A; Pollock KG; Powell N; Wilson R; McCall F; Fiander A; Soldan K
J Clin Pathol; 2015 Feb; 68(2):135-40. PubMed ID: 25410654
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3.
Castle PE; Schiffman M; Wheeler CM; Wentzensen N; Gravitt PE
Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1675-81. PubMed ID: 20615885
[TBL] [Abstract][Full Text] [Related]
16. The role of human papillomavirus genotyping for detecting high-grade intraepithelial neoplasia or cancer in HPV-positive women with normal cytology: a study from a hospital in northeastern China.
Zhang J; Zhang D; Yang Z; Wang X; Wang D
BMC Cancer; 2020 May; 20(1):443. PubMed ID: 32429919
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy.
Mariani L; Monfulleda N; Alemany L; Vizza E; Marandino F; Vocaturo A; Benevolo M; Quirós B; Lloveras B; Klaustermeier JE; Quint W; de Sanjosé S; Bosch FX
BMC Cancer; 2010 Jun; 10():259. PubMed ID: 20525370
[TBL] [Abstract][Full Text] [Related]
18. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.
Kreimer AR; Rodriguez AC; Hildesheim A; Herrero R; Porras C; Schiffman M; González P; Solomon D; Jiménez S; Schiller JT; Lowy DR; Quint W; Sherman ME; Schussler J; Wacholder S;
J Natl Cancer Inst; 2011 Oct; 103(19):1444-51. PubMed ID: 21908768
[TBL] [Abstract][Full Text] [Related]
19. The potential impact of human papillomavirus vaccination in contemporary cytologically screened populations may be underestimated: an observational retrospective analysis of invasive cervical cancers.
Powell N; Boyde A; Tristram A; Hibbitts S; Fiander A
Int J Cancer; 2009 Nov; 125(10):2425-7. PubMed ID: 19585507
[TBL] [Abstract][Full Text] [Related]
20. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.
Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Pearse A; Montoya GD; Robertson M; Shearman CA; Castle PE;
Int J Cancer; 2013 Jan; 132(1):198-207. PubMed ID: 22532127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
